Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 27, 2023 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union

PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
July 22, 2022 07:35 ET | Source: The Insight Partners

Enzyme Replacement Therapy Market Worth $15.18 Billion by 2028 at 6.8% CAGR Led by Hospitals Segment (49% Market Share in 2021) Global Analysis by The Insight Partners

New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
September 15, 2021 20:00 ET | Source: DelveInsight Business Research LLP

DelveInsight Estimates a Promising Picture of Pompe Disease Pipeline Landscape in the Coming Years as Key Pharma Companies Bolster Rare Disease Pipeline

Los Angeles, USA, Sept. 15, 2021 (GLOBE NEWSWIRE) -- DelveInsight Estimates a Promising Picture of Pompe Disease Pipeline Landscape in the Coming Years as Key Pharma Companies Bolster Rare Disease...
January 29, 2020 10:27 ET | Source: Asklepios BioPharmaceutical, Inc.

AskBio Launches AskFirst™ Patient Advocacy Program to Educate and Support Participants in Gene Therapy Clinical Trials

RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, today introduced...
December 19, 2019 08:25 ET | Source: Asklepios BioPharmaceutical, Inc.

AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease

– Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and...
January 11, 2016 11:30 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease at 34th Annual J.P. Morgan Annual Healthcare Conference

SAN RAFAEL, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced interim results from INSPIRE, a Phase 2 trial for reveglucosidase alfa, a fusion...
May 04, 2015 09:00 ET | Source: Cortex Pharmaceuticals, Inc.

Cortex Pharmaceuticals, Inc. Announces Publication of Research Results on the Use of Ampakines CX1739 and CX717 in the Treatment of Respiratory Disorders

GLEN ROCK, N.J., May 4, 2015 (GLOBE NEWSWIRE) -- Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company") announces the recent publication of two key scientific papers co-authored by the...